Efficacy and Safety of Dapagliflozin in Patients With Inadequately Controlled Type 1 Diabetes (the DEPICT-2 Study): 24-Week Results From a Randomized Controlled Trial.

Chantal Mathieu Paresh Dandona Pieter GillardPeter SeniorChristoph HasslacherEiichi ArakiMarcus LindStephen C BainSerge A JabbourNiki AryaLars HansenFredrik ThorénAnna Maria Langkildenull null

Published in: Diabetes care (2018)

Dapagliflozin as adjunct therapy to adjustable insulin in patients with type 1 diabetes was well tolerated and improved glycemic control with no increase in hypoglycemia versus placebo but with more DKA events.

Keyphrases

glycemic control
type diabetes
blood glucose
weight loss
insulin resistance
cardiovascular disease
clinical trial
stem cells
adipose tissue
randomized controlled trial
bone marrow
metabolic syndrome
placebo controlled
phase iii
cell therapy
open label